Pages that link to "Q45839247"
Jump to navigation
Jump to search
The following pages link to Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response (Q45839247):
Displaying 24 items.
- Newcastle disease virus (NDV): brief history of its oncolytic strains (Q33841589) (← links)
- Oncolytic viruses (Q33888224) (← links)
- T cell-mediated immunotherapy of metastases: state of the art in 2005. (Q36210864) (← links)
- Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: a novel general strategy for the generation of potent cancer vaccines (Q37362679) (← links)
- Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer (Q37535829) (← links)
- Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine (Q40766761) (← links)
- New insights into tumor-host interactions in lymphoma metastasis (Q41139934) (← links)
- More than one component of the Newcastle disease virus particle is capable of interferon induction (Q41478708) (← links)
- Viral hemagglutinin augments peptide-specific cytotoxic T cell responses (Q41522249) (← links)
- Anti-CD2 antibodies induce T cell unresponsiveness in vivo (Q41659103) (← links)
- Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice (Q41763853) (← links)
- Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences (Q42638946) (← links)
- Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus (Q44438732) (← links)
- Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4 and CD8 immune T cell cooperation (Q45847458) (← links)
- In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients (Q45856337) (← links)
- Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme (Q48731885) (← links)
- In Vitro Synergistic Enhancement of Newcastle Disease Virus to 5-Fluorouracil Cytotoxicity against Tumor Cells (Q50905634) (← links)
- Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! (Q53739132) (← links)
- Immunobiology and Immunotherapy of Cancer Metastases Ten-Year Studies in an Animal Model Resulting the Design of an Immunotherapy Procedure now under Clinical Testing (Q58357809) (← links)
- Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma (Q67753693) (← links)
- In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity (Q67939633) (← links)
- A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo (Q71235535) (← links)
- Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens (Q72656148) (← links)
- Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy (Q93079047) (← links)